Vaccines against myasthenia gravis

Expert Opinion on Biological Therapy

Volumn 5, Issue 7, 2005, Pages 983-995

  Berrih Aknin, Sonia ^a,b   Fuchs, Sara ^b   Souroujon, Miriam C ^b,c  

^a CNRS   (France)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Acetylcholine receptor; Autoimmune; Dendritic cells; Myasthenia gravis; Regulatory cells; T cells; Tolerisation; Vaccination

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HLA DR3 ANTIGEN; IDIOTYPIC ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; NICOTINIC RECEPTOR; RECEPTOR ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; CELL TRANSFER; DENDRITIC CELL; DOWN REGULATION; DRUG MECHANISM; HELPER CELL; IMMUNOLOGICAL TOLERANCE; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOGENESIS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THYMECTOMY; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; HUMANS; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, NICOTINIC; T-LYMPHOCYTES; VACCINES;

ANIMALIA;

EID: 22744447512     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.7.983     Document Type: Review

References (100)

1. AHARONOV A, ABRAMSKY O, TARRAB-HAZDAI R, FUCHS S: Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 2:340-342. First evidence of the presence of antibodies against AChR in MG patients.
2. LINDSTROM JM, SEYBOLD ME, LENNON VA, WHITTINGHAM S, DUANE DD: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 26:1054-1059.
3. DRACHMAN DB, ADAMS RN, JOSIFEK LF, SELF SG: Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. (1982) 307:769-775.
4. TZARTOS SJ, SOPHIANOS D, ZIMMERMAN K, STARZINSKI-POWITZ A: Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate. J. Immunol. (1986) 136:3231-3238.
5. ENGEL AG, LAMBERT EH, HOWARD FM: Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. (1977) 52:267-280.
6. + T cells from MG patients proliferate in the presence of the AChR α-subunit.
7. MELMS A, SCHALKE BC, KIRCHNER T, MULLER-HERMELINK HK, ALBERT E, WEKERLE H: Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. (1988) 81:902-908.
8. SUN JB, HARCOURT G, WANG ZY et al.: T cell responses to human recombinant acetylcholine receptor-alpha subunit in myasthenia gravis and controls. Eur. J. Immunol. (1992) 22:1553-1559. Quantification by enzme-linked immunospot of the number of peripheral blood mononuclear cells reacting to the AChR α-subunit.
9. ASTHANA D, FUJII Y, HUSTON GE, LINDSTROM J: Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin. Immunol. Immunopathol. (1993) 67:240-248.
10. ROSENBERG JS, OSHIMA M, ATASSI MZ: B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol. (1996) 157:3192-3199.
11. KIRSHNER SL, KATZ-LEVY Y, WIRGUIN I, ARGOV Z, MOZES E: Fine specificity of T cell lines and clones that are capable of inducing autoimmune manifestations in mice. Cell. Immunol. (1994) 157:11-28.
12. VENUTA F, RENDINA EA, DE GIACOMO T et al.: Thymectomy for myasthenia gravis: a 27-year experience. Eur. J. Cardiothorac. Surg. (1999) 15:621-624; discussion 624-625.
13. BEGHI E, ANTOZZI C, BATOCCHI AP et al.: Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J. Neurol. Sci. (1991) 106:213-220.
14. BERRIH S, MOREL E, GAUD C, RAIMOND F, LE BRIGAND H, BACH JF: Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology (1984) 34:66-71. Description of a clear association between thymic pathology and the anti-AChR antibody titre, showing that the highest titres are found in patients with thymic hyperplasia.
15. SPURKLAND A, GILHUS NE, RONNINGEN KS, AARLI JA, VARTDAL F: Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens (1991) 37:90-93.
16. KUKS JB, OOSTERHUIS HJ, LIMBURG PC, THE TH: Anti-acerylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J. Autoimmun. (1991) 4:197-211.
17. TRUFFAULT F, COHEN-KAMINSKY S, KHALIL I, LEVASSEUR P, BERRIH-AKNIN S: Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann. Neurol. (1997) 41:731-741.
18. COHEN-KAMINSKY S, LEPRINCE C, GALANAUD P, RICHARDS Y, BERRIH-AKNIN S: B- and T-cell activation in the thymus of patients with myasthenia gravis. Thymus (1989) 14:187-193.
19. COHEN-KAMINSKY S, LEVASSEUR P, BINET JP, BERRIH-AKNIN S: Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis. J. Neuroimmunol. (1989) 24:75-85.
20. LEPRINCE C, COHEN-KAMINSKY S, BERRIH-AKNIN S et al.: Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J. Immunol. (1990) 145:2115-2122. B cells purified from MG thymic hyperplasia are activated and produce antibodies against AChR.
21. MOULIAN N, BIDAULT J, TRUFFAULT F, YAMAMOTO AM, LEVASSEUR P, BERRIH-AKNIN S: Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood (1997) 89:3287-3295. Description of Fas as a marker of activated cells in the MG thymus and correlations with anti-AChR antibody titres.
22. WAKKACH A, GUYON T, BRUAND C, TZARTOS S, COHEN-KAMINSKY S, BERRIH-AKNIN S: Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J. Immunol. (1996) 157:3752-3760. Expression of AChR in human thymic epithelial cells at both the mRNA level and the protein level (α-subunit).
23. WAKKACH A, POEA S, CHASTRE E et al.: Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am. J. Pathol. (1999) 155:1229-1240.
24. ZHENG Y, WHEATLEY LM, LIU T, LEVINSON AI: Acetylcholine receptor alpha subunit mRNA expression in human thymus: augmented expression in myasthenia gravis and upregulation by interferon-gamma. Clin. Immunol. (1999) 91:170-177. AChR expression is increased in MG thymuses.
25. POËA-GUYON S, CHRISTADOSS P, LE PANSE R et al.: Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J. Immunol. (2005) 174(10):5941-5949.
26. SHELTON GD: Acquired myasthenia gravis: what we have learned from experimental and spontaneous animal models. Vet. Immunol. Immunopathol. (1999) 69:239-249.
27. LINK H, XIAO BG: Rat models as tool to develop new immunotherapies. Immunol. Rev. (2001) 184:117-128.
28. MEINL E, KLINKERT WE, WEKERLE H: The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am. J. Pathol. (1991) 139:995-1008. The thymus is not involved in the experimental model of myasthenia in rats.
29. BARTFELD D, FUCHS S: Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor. Proc. Natl. Acad. Sci. USA (1978) 75:4006-4010. This is the first demonstration that EAMG is suppressed by denatured Torpedo AChR.
30. WEINER HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today (1997) 18:335-343.
31. TOUSSIROT EA: Oral tolerance in the treatment of rheumatoid arthritis. Curr. Drug Targets Inflamm. Allergy (2002) 1:45-52.
32. WANG ZY, QIAO J, LINK H: Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. (1993) 44:209-214.
33. OKUMURA S, MCINTOSH K, DRACHMAN DB: Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann. Neurol. (1994) 36:704-713.
34. MA CG, ZHANG GX, XIAO BG, LINK J, OLSSON T, LINK H: Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. (1995) 58:51-60.
35. DRACHMAN DB, OKUMURA S, ADAMS RN, MCINTOSH KR: Oral tolerance in myasthenia gravis. Ann. NY Acad. Sci. (1996) 778:258-272.
36. SHI FD, BAI XF, LI HL, HUANG YM, VAN DER MEIDE PH, LINK H: Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. Clin. Exp. Immunol. (1998) 111:506-512.
37. TZARTOS SJ, LINDSTROM JM: Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl. Acad. Sci. USA (1980) 77:755-759. Identification and localisation of the MIR of the AChR.
38. BARCHAN D, ASHER O, TZARTOS SJ, FUCHS S, SOUROUJON MC: Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur. J. Immunol. (1998) 28:616-624.
39. IM SH, BARCHAN D, FUCHS S, SOUROUJON MC: Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment [see comments]. J. Clin. Invest. (1999) 104:1723-1730. Demonstration that ongoing EAMG in rats is suppressed by oral or nasal tolerance with a xenogeneic or syngeneic recombinant fragment corresponding to the extracellular domain of the AChR α-subunit.
40. MAITI PK, FEFERMAN T, IM SH, SOUROUJON MC, FUCHS S: Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. (2004) 152:112-120. See [39].
41. BARCHAN D, SOUROUJON MC, IM SH, ANTOZZI C, FUCHS S: Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc. Natl. Acad. Sci. USA (1999) 96:8086-8091. See [39].
42. IM S, BARCHAN D, FUCHS S, SOUROUJON MC: Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. (2000) 111:161-168. See [39].
43. SOUROUJON MC, CARMON S, FUCHS S: Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides. Immunol. Lett. (1992) 34:19-25.
44. SOUROUJON MC, CARMON S, FUCHS S: Regulation of experimental autoimmune myasthenia gravis by synthetic peptides of the acetylcholine receptor. Ann. NY Acad. Sci. (1993) 681:332-334.
45. ATASSI MZ, RUAN KH, JINNAI K, OSHIMA M, ASHIZAWA T: Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc. Natl. Acad. Sci. USA (1992) 89:5852-5856.
46. WU B, DENG C, GOLUSZKO E, CHRISTADOSS P: Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. (1997) 159:3016-3023.
47. KARACHUNSKI PI, OSTLIE NS, OKITA DK, GARMAN R, CONTI-FINE BM: Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J. Neuroimmunol. (1999) 93:108-121.
48. SHENOY M, OSHIMA M, ATASSI MZ, CHRISTADOSS P: Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. (1993) 66:230-238.
49. KARACHUNSKI PI, OSTLIE NS, OKITA DK, CONTI-FINE BM: Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. (1997) 100:3027-3035.
50. BAGGI F, ANDREETTA F, CASPANI E et al.: Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J. Clin. Invest. (1999) 104:1287-1295.
51. DENG C, GOLUSZKO E, CHRISTADOSS P: Fas/fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor t cell epitope tolerance. J. Immunol. (2001) 166:3458-3467.
52. SOUROUJON MC, MAITI PK, FEFERMAN T, IM SH, RAVEH L, FUCHS S: Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Ann. NY Acad. Sci. (2003) 998:533-536.
53. IM SH, BARCHAN D, SOUROUJON MC, FUCHS S: Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol. (2000) 165:3599-3605.
54. IM SH, BARCHAN D, FEFERMAN T, RAVEH L, SOUROUJON MC, FUCHS S: Protective molecular mimicry in experimental myasthenia gravis. J. Neuroimmunol. (2002) 126:99-106.
55. SELA M, MOZES E: Therapeutic vaccines in autoimmunity. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):14586-14592.
56. ZHANG GX, XIAO BG, YU LY, VAN DER MEIDE PH, LINK H: Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. (2001) 113:10-18. Evidence for the deleterious role of IL-10 in the induction of EAMG.
57. POUSSIN MA, GOLUSZKO E, HUGHES TK, DUCHICELLA SI, CHRISTADOSS P: Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. (2000) 111:152-160. See [56].
58. OSTLIE NS, KARACHUNSKI PI, WANG W, MONFARDINI C, KRONENBERG M, CONTI-FINE BM: Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J. Immunol. (2001) 166:4853-4862. See [56].
59. VANDERLUGT CL, MILLER SD: Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. (2002) 2:85-95.
60. FEFERMAN T, IM SH, FUCHS S, SOUROUJON MC: Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J. Neuroimmunol. (2003) 140:153-158.
61. SOUROUJON MC, BARCHAN D, FUCHS S: Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes. Immunol. Lett. (1985) 9:331-336.
62. SOUROUJON MC, PACHNER AR, FUCHS S: The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology (1986) 36:622-625.
63. ARAGA S, LEBOEUF RD, BLALOCK JE: Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor [published erratum appears in Proc. Natl. Acad. Sci. USA (1994) 91 (4):1598]. Proc. Natl. Acad. Sci. USA (1993) 90:8747-8751.
64. LOUTRARI H, KOKLA A, TZARTOS SJ: Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur. J. Immunol. (1992) 22:2449-2452.
65. ARAGA S, GALIN FS, KISHIMOTO M, ADACHI A, BLALOCK JB: Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. J. Immunol. (1996) 157:386-392.
66. VERSCHUUREN JJ, GRAUS YM, VAN BREDA VRIESMAN PJ, TZARTOS S, DE BAETS MH: In vivo effects of neonatal administration of antiidiotype antibodies on experimental autoimmune myasthenia gravis. Autoimmunity (1991) 10:173-179.
67. XIAO BG, DUAN RS, LINK H, HUANG YM: Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell. Immunol. (2003) 223:63-69.
68. YARILIN D, DUAN R, HUANG YM, XIAO BG: Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. (2002) 127:214-219.
69. DUAN RS, ADIKARI SB, HUANG YM, LINK H, XIAO BG: Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol. Dis. (2004) 16:461-467.
70. AISSAOUI A, KLINGEL-SCHMITT I, COUDERC J et al.: Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis [see comments]. Ann. Neurol. (1999) 46:559-567. Evidence for a pathogenic role of Vβ5.1-expressing T cells from HLA-DR3 patients.
71. JAMBOU F, ZHANG W, MENESTRIER M et al.: Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis. J. Clin. Invest. (2003) 112:265-274.
72. OFFNER H, HASHIM GA, VANDENBARK AA: Immunity to T cell receptor peptides: theory and applications. Regul. Pept. (1994) 51:77-90.
73. XU L, VILLAIN M, GALIN FS, ARAGA S, BLALOCK JE: Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells. Cell. Immunol. (2001) 208:107-114.
74. BENSINGER SJ, WALSH PT, ZHANG J et al.: Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J. Immunol. (2004) 172:5287-5296.
75. HORWITZ DA, ZHENG SG, GRAY JD, WANG JH, OHTSUKA K, YAMAGIWA S: Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. (2004) 16:135-143.
76. WOOD KJ, SAKAGUCHI S: Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. (2003) 3:199-210.
77. SHEVACH EM: Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol. (2000) 18:423-449.
78. BAECHER-ALLAN C, VIGLIETTA V, HAFLER DA: Human CD4+CD25+ regulatory T cells. Semin. Immunol. (2004) 16:89-98.
79. + cells.
80. VIGLIETTA V, BAECHER-ALLAN C, WEINER HL, HAFLER DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. (2004) 199:971-979.
81. KRIEGEL MA, LOHMANN T, GABLER C, BLANK N, KALDEN JR, LORENZ HM: Defective suppressor function of human CD4+CD25+ regulatory T cells in autoimmune polyglandular syndrome Type II. J. Exp. Med. (2004) 199:1285-1291.
82. LINDLEY S, DAYAN CM, BISHOP A, ROEP BO, PEAKMAN M, TREE TI: Defective suppressor function in CD4(+)CD25(+) T-cells from patients with Type 1 diabetes. Diabetes (2005) 54:92-99.
83. HUANG YM, PIRSKANEN R, GISCOMBE R, LINK H, LEFVERT AK: Circulating CD4CD25 and CD4CD25 T cells in myasthenia gravis and in relation to thymectomy. Scand J. Immunol. (2004) 59:408-414.
84. SUN Y, QIAO J, LU CZ, ZHAO CB, ZHU XM, XIAO BG: Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy. Clin. Immunol. (2004) 112:284-289.
85. + cells in MG patients.
86. BLUESTONE JA, TANG Q: Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):14622-14626.
87. CHATENOUD L: CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. (2003) 3:123-132.
88. MCINTOSH KR, LINSLEY PS, DRACHMAN DB: Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. Cell. Immunol. (1995) 166:103-112.
89. IM SH, BARCHAN D, MAITI PK, FUCHS S, SOUROUJON MC: Blockade of cd40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of th1 differentiation and up-regulation of ctla-4. J. Immunol. (2001) 166:6893-6898.
90. IM SH, BARCHAN D, MAITI PK, RAVEH L, SOUROUJON MC, FUCHS S: Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. (2001) 15:2140-2148.
91. STEINMAN L: Immune therapy for autoimmune diseases. Science (2004) 305:212-216.
92. KOMAGATA Y, WEINER HL: Oral tolerance. Rev. Immunogenet. (2000) 2:61-73.
93. COHEN IR, QUINTANA FJ, MIMRAN A: Tregs in T cell vaccination: exploring the regulation of regulation. J. Clin. Invest. (2004) 114:1227-1232.
94. FIGDOR CG, DE VRIES IJ, LESTERHUIS WJ, MELIEF CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. (2004) 10:475-480.
95. LESTERHUIS WJ, DE VRIES IJ, ADEMA GJ, PUNT CJ: Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann. Oncol. (2004) 15(Suppl. 4):iv145-iv151.
96. RIESER C, RAMONER R, HOLTL L et al.: Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int. (1999) 63:151-159.
97. WIENDL H, HOHLFELD R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 16:183-200.
98. rd, WHITACRE CC: Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm. Res. (1999) 48:106-119.
99. MISHINA M, TAKAI T, IMOTO K et al.: Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature (1986) 321:406-411.
100. BEESON D, MORRIS A, VINCENT A, NEWSOM-DAVIS J: The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. EMBO J. (1990) 9:2101-2106.